Ypsomed Holding AG (SIX:YPSN) shares declined 1.2% on Thursday after earlier falling as much as 3% during the session, following a critical initiation of coverage by Jefferies that questioned the injectables device maker’s medium-term growth outlook and valuation.
Jefferies launched coverage with an Underperform rating and set a CHF280 price target. The firm’s model projects fiscal 2030 EBIT about 7% lower than consensus and a discounted cash flow valuation that implies roughly 18% downside from prevailing share prices.
Central to Jefferies’ concern is Ypsomed’s exposure to the Novo Nordisk product Cagrisema. The broker notes that consensus fiscal 2030 Cagrisema estimates have been reduced by 54% since the company’s September 2025 capital markets day, yet Ypsomed’s share price has returned to pre-readout levels while medium-term consensus appears largely unchanged. Jefferies interprets that as a potential under-reflection of Cagrisema’s diminished commercial prospects in current forecasts.
In Jefferies’ projections, Cagrisema could contribute about CHF78 million, equivalent to 8.2% of Ypsomed’s fiscal 2030 sales. The analyst warns the drug may account for between 10% and 25% of incremental year-over-year growth for Ypsomed over the medium term, making its ultimate performance material to the company’s outlook.
The broker says the risk around Cagrisema increased after Novo Nordisk’s first quarter 2026 update, which confirmed the termination of the Cagrisema co-formulation. Jefferies suggests that decision could constrain the product’s scalability and commercial viability, amplifying downside risk to Ypsomed’s medium-term sales trajectory.
Jefferies also pointed to Ypsomed’s trimming of medium-term capital expenditure to CHF1.3 billion as an indication of weaker demand, especially linked to Cagrisema. The firm estimates that the capex reduction equates to roughly a CHF80 million decline in peak sales potential.
"We see Cagrisema exposure weighing on MT sales growth, driving downside risk to consensus forecasts given the materiality to incremental growth," Jefferies commented.
Beyond top-line concerns, Jefferies raised issues about margin expansion. The brokerage highlighted that Ypsomed’s medium-term guidance implies a reduction in margins as the company shifts its mix toward lower-priced commercial products.
The analyst action and accompanying commentary drove the intraday share weakness. Market participants will likely watch how consensus forecasts evolve and whether medium-term estimates for both Cagrisema and Ypsomed’s broader commercial opportunity are adjusted in response to the factors Jefferies set out.